Evotec
$7.1
256
+$0+0% Tuesday 20:00
Statistics
Day High
6.96
Day Low
6.96
52W High
24.61
52W Low
6.57
Volume
100
Avg. Volume
58
Mkt Cap
1.31B
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
6NovExpected
Expected EPS
-0.04797136432
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow EVOTF. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Fidelity National Information Services
FIS
Mkt Cap44.98B
Global Payments
GPN
Mkt Cap28.25B
Block
SQ
Mkt Cap40.68B
PayPal
PYPL
Mkt Cap74.05B
Mastercard Incorporated
MA
Mkt Cap446.53B
Visa
V
Mkt Cap537.78B
Automatic Data Processing
ADP
Mkt Cap112.51B
WEX
WEX
Mkt Cap7.85B
About
Biotechnology
Health Technology
Pharmaceuticals: Major
Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as diabetes and complications of diabetes, fibrosis, infectious diseases, CNS diseases, oncology, pain and inflammation, immunology, rare diseases, respiratory diseases, and women's health. It has collaboration agreements with Bayer AG; Lilly; Chinook Therapeutics; Novo Nordisk A/S; Galapagos; Pfizer Inc.; CONBA Pharmaceutical Co., Ltd.; Bristol Myers Squibb Company; Zhejiang JingXin Pharmaceutical Co., Ltd; Kazia Therapeutics; Apeiron Biologics; and Takeda Pharmaceuticals. The company was formerly known as Evotec AG and changed its name to Evotec SE in April 2019. Evotec SE was incorporated in 1993 and is headquartered in Hamburg, Germany.
Show more...
CEO
Werner Lanthaler
Employees
5022
Country
DE
ISIN
DE0005664809